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Oxidative stress and energy depletion are believed to participate in hippocampal neuronal damage after forebrain ischemia.
This study has been initiated to investigate the potential neuroprotective eﬀects of probucol, a lipid-lowering drug with strong
antioxidant properties, against transient forebrain ischemia-induced neuronal damage and biochemical abnormalities in rat
hippocampal CA1 region. Adult male Wistar albino rats were subjected to forebrain ischemia and injected with probucol for
the next 7 successive days, and compared to controls. Forebrain ischemia resulted in a signiﬁcant decrease in the number of
intact neurons (77%), glutathione (GSH), and adenosine triphosphate (ATP), and a signiﬁcant increase in thiobarbituric acid
reactive substances (TBARS) and total nitrate/nitrite, (NOx) production in hippocampal tissues. The administration of probucol
attenuated forebrainischemia-induced neuronaldamage,manifestedas acomplete reversalofthe decrease inthe number ofintact
neurons, ATP and GSH and the increase in TBARS and NOx in hippocampal tissues. This study demonstrates that probucol
treatment abates forebrain ischemia-induced hippocampal neuronal loss, energy depletion, and oxidative stress in hippocampal
CA1 region. Thus, probucol could be a promisingneuroprotective agent in the treatment of forebrain ischemia.
1.Introduction
Damage to brain tissue due to ischemic stroke is the ﬁrst
leading cause of fatal neurological disease, the third cause of
death after heart disease and cancer, and is the major cause
of adult long-term disability in industrialized countries [1–
3]. A signiﬁcant number of strokes is a consequence of the
occlusion of one of the main or secondary cerebral arteries
[4, 5]. Transient global ischemia (forebrain ischemia), occur-
ring during cardio-respiratory arrest in patients or in experi-
mental animals, induces selective and delayed neuronal cell
death. The hippocampus, particularly the CA1 pyramidal
neurons, is the most severely aﬀected brain structure by
global ischemia [2, 5]. The damage to the hippocampal CA1
sector develops 3–7 days after untreated forebrain ischemia
inrats,gerbil,andhuman[2,6].Forebrainischemiaiscaused
by a deﬁciency in the blood supply to hippocampal neurons,
leading to disturbances in energy metabolism that lead to
a decrease in glucose utilization, with a consequent decrease
in the production of ATP and phosphocreatine [7, 8]. This
leads to anaerobic glycolysis and lactic acidosis followed
by membrane depolarization, inﬂux of calcium ions, and
the release of glutamate into the extracellular space that
induces pro-oxidant enzymes such as inducible nitric oxide
synthase (iNOS)[9, 10].Mostofthese changesare associated
with a massive production of reactive oxygen species (ROS),
which causes severe oxidative injury to the brain tissue [11].
Also, reperfusion is associated with a massive production
of toxic ROS that potentiates the initial brain damage
caused by forebrain ischemia [12]. The accumulation of
the toxic ROS markedly increases the susceptibility of brain
tissuestooxidativedamageviamembranelipidperoxidation,
protein, and DNA oxidation [11–13]. Earlier studies have
reported that oxidative damage is a primary factor in various
models of acute brain damage including forebrain ischemia
[13–15]. Moreover, increased oxidative stress biomarkers2 Oxidative Medicine and Cellular Longevity
and depletion of enzymatic and nonenzymatic antioxidants
have been reported in many diseases including forebrain
ischemia-inducedneuronaldamage[16,17].Thus,onestrat-
egy to protect the brain against forebrain ischemia-induced
hippocampal neuronal damage is to decrease oxidative
damage by neutralizing the toxic ROS that are produced in
the ischemic tissues.
Probucol is a clinically used cholesterol-lowering drug
with pronounced antioxidant eﬀect [18]. Besides its antiox-
idant properties, probucol was shown to protect against
diabetes and doxorubicin-induced cardiomyopathy associ-
ated with oxidative stress by stimulating the endogenous
antioxidant enzymes [19–21]. Previous studies have demon-
strated that probucol improved survival of rats with large
myocardial infarction by reducing cardiac ﬁbrosis and ex-
pression of inﬂammatory cytokines [22, 23]. In doxorubicin
cardiomyopathic rat model, probucol prevents the develop-
ment of doxorubicin-induced cardiomyopathy by increas-
ing ATP production in cardiac tissues [24]. Moreover, in
isoproterenol-induced rat model of heart failure, probucol
was shown to attenuate oxidative stress and energy depletion
[25]. Probucol attenuates the progression of congestive
heart failure and cardiomyocyte apoptosis induced by is-
chemia reperfusion [26]. It protected rat heart against is-
chemia-reperfusion arrhythmias-induced cardiac damage
[27]. Recently, it has been reported that other cholesterol
lowering drugs such as simvastatin have been shown to
be neuroprotective against cerebral ischemia-induced neu-
ronal damage [28–31]. Although the therapeutic potential
of probucol for the treatment of many forms of heart
diseases, including myocardial ischemia reperfusion, is well
documented, its direct role in forebrain ischemia-induced
hippocampal damage has not been studied yet. Therefore,
this study aimed to examine whether or not probucol would
protect rat hippocampal neurons from death after forebrain
ischemia.
2.Results
The eﬀects of 10min of forebrain ischemia, probucol and
their combination on the number of intact neurons in the
CA1 region of rat hippocampus, are shown in Figure 1.
Histopathological examination of the hippocampal CA1
region from the control (Figure 1(a)), sham-operated
(Figure 1(b)), and probucol-treated (Figure 1(d)) groups
revealed normal intact neurons. However, 7 days after the
forebrain ischemia, there was widespread damage to the CA1
region of the hippocampus, as demonstrated by a highly
signiﬁcant 77% decrease in the number of intact neurons
(Figure 1(c)). Neuronal death in the CA1 hippocampal
sector was signiﬁcantly reduced by the administration of
probucol immediately after ischemia and continued for 7
successivedays (Figure 1(e)).This was manifested as a signif-
icant increase in the number of intact neurons as compared
to the ischemia group.
The eﬀects of forebrain ischemia, probucol and their
combination on TBARS level, an index of lipid peroxidation,
in hippocampal tissues are shown in Figure 2.F o r e b r a i n
ischemia induced a signiﬁcant 71% increase in hippocampal
TBARSlevelcomparedwithbothsham-operatedandcontrol
groups. Treatment of ischemic rats with probucol resulted
in complete reversal of the forebrain ischemia-induced
increase in TBARS level to the control values. However,
the administration of probucol alone for 7 successive days
resulted in nonsigniﬁcant changes in hippocampal TBARS.
Figure 3 shows the eﬀects of probucol, ischemia,
and their combination on GSH level, which reﬂects the
cellular nonenzymatic antioxidant defense system in rat hip-
pocampal tissues. Forebrain ischemia induced a signiﬁcant
32%decreaseinhippocampal GSHlevel.The administration
of probucol immediately after ischemia and continued for
7 successive days resulted in a reversal of the forebrain
ischemia-induceddecreaseinGSHleveltothecontrolvalues.
The eﬀects of forebrain ischemia, probucol and their
combination on NOx concentrations in rat hippocampal
tissues, are shown in Figure 4. Forebrain ischemia induced
a signiﬁcant 260% increase in NOx concentration in hip-
pocampal tissues. Treatment of ischemic rats with probucol
resulted in a reversal of the forebrain ischemia-induced
increase in NOx concentration to the control values. The
administration of probucol alone for 7 successive days re-
sulted in nonsigniﬁcant changes in hippocampal NOx con-
centration.
Figure 5 shows the eﬀects of 10min forebrain ischemia,
probucol and their combination on ATP level in the rat hip-
pocampus. Forebrain ischemia resulted in a signiﬁcant 51%
decrease in hippocampalATP levelcomparedwith thesham-
operated and control groups. Administration of probucol
(61mg/kg)alonefor7successivedaysresultedinanonsignif-
icant increase in hippocampal ATP level.However,treatment
of ischemic rats with probucol immediately after ischemia
and continued for 7 successive days resulted in complete
reversal of the forebrain ischemia-induced depletion of ATP
level in hippocampal tissues to the control values.
3.Discussion
In the present study, the administration of probucol to rats
prevented delayed neuronal death of the hippocampal CA1
region induced by transient forebrain ischemia. This protec-
tion was evident from the signiﬁcant reduction in neuronal
cell death in the hippocampal CA1 region, restoration of
the non-protein-SH contents and reduction in TBARS pro-
duction, prevention of the elevation in NOx concentrations,
and normalization of ATP level after forebrain ischemia.
Additionally, the administration of probucol resulted in
complete recovery of the decrease in ATP levels observed
after ischemia compared to the control value.
Results of this study indicated that 10min of forebrain
ischemia in rats induced massive and selective neuronal
damage in vulnerableregions, namely, the hippocampal CA1
region. About 77% of the hippocampal CA1 neurons died
after 7 days postischemic reperfusion (Figure 1(c)). These
results conﬁrm those previously reported [3, 14, 15, 32]. The
administration of probucol to ischemic rats oﬀered protec-
tion against hippocampal CA1 neuronal damage induced byOxidative Medicine and Cellular Longevity 3
(a) (b)
(c) (d)
(e)
Figure1:Eﬀects offorebrainischemia,probucolandtheircombinationonthenumber ofintactneuronsinCA1subregionofrathippocam-
pus.HippocampalCA1subregionfrom thecontrol(a),sham-operated(b),andprobucol-treated (d) groups showingnormalintactneurons
(×20). Hippocampal CA1 subregion from rats subjected to 10min forebrain ischemia group (c) showed severe and marked decrease in the
number of intact neurons (×20). Hippocampal CA1 subregion from rats treated with probucol plus ischemia group (e) showed normal
intact neurons (×20).
the 10min of forebrain ischemia as evidenced by the fact
that probucol rescued most of CA1 pyramidal neurons from
ischemic death (Figure 1(e)).
In the present study, the concentration of ATP in rat
hippocampus was measured 7 days after reperfusion and
was found to be decreased by 51% of the control values
(Figure 5). These results are consistent with those previously
reported that in CA1 region of the hippocampus, a decrease
in ATP and phosphocreatine occurs beyond 48 hours of
reperfusion [7, 8]. Under similar experimental condition,
previous studies by the author have reported that forebrain
ischemia decreased ATP production in rat hippocampus 7
days after reperfusion [14, 15]. This observed decrease in
ATP productionin rat hippocampus afterforebrain ischemia
could be a secondary event following the inhibition of sub-
strate utilization and mitochondrial oxidative phosphoryla-
tion. It has been reported that alterations in mitochondrial
respiration can induce secondary depletion of both phos-
phocreatine and ATP [8], as well as increased levels of brain
lactate and decreased activity of pyruvate dehydrogenase4 Oxidative Medicine and Cellular Longevity
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Figure 2: Eﬀects of forebrain ischemia, probucol, and their com-
bination on TBARS level, an index of lipid peroxidation, in hip-
pocampal tissues in each group. Data are presented as mean ±
S.E.M. (n = 10). ∗ and # indicate signiﬁcant change from control
and ischemia, respectively, at P<0.05 using ANOVA followed by
Tukey-Kramer as a post-ANOVA test.
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Figure 3: Eﬀects of forebrain ischemia, probucol, and their combi-
nation on GSH level, an index antioxidant, in hippocampal tissues
in each group. Data are presented as mean ± S.E.M. (n = 10).
∗ and # indicate signiﬁcant change from control and ischemia,
respectively, at P<0.05 using ANOVA followed by Tukey-Kramer
as a post-ANOVA test.
enzyme [33]. Furthermore, the accumulation of the toxic
ROSfollowing ischemia markedly increases thesusceptibility
of brain tissues to oxidative damage via membrane lipid
peroxidation with the consequent decrease in the activity of
many mitochondrial enzymes [34, 35].
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Figure 4: Eﬀects of forebrain ischemia, probucol, and their combi-
nation on NOx concentrations, an index reactive nitrogen species,
inhippocampaltissuesineachgroup. Dataarepresented asmean ±
S.E.M. (n = 10). ∗ and # indicate signiﬁcant change from control
and ischemia, respectively, at P<0.05 using ANOVA followed by
Tukey-Kramer as a post-ANOVA test.
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Figure 5: Eﬀects of forebrain ischemia, probucol, and their com-
bination on ATP concentrations, an index of energy production
and mitochondrial function, in hippocampal tissues in each group.
Data are presented as mean ± S.E.M. (n = 10). ∗ and # indicate
signiﬁcant change from control and ischemia, respectively, at P<
0.05 using ANOVA followed by Tukey-Kramer as a post-ANOVA
test.
Forebrainischemiasigniﬁcantlyincreasedlipidperoxida-
tion in the hippocampus, which was measured by TBARS,
as compared to levels in the normal hippocampus. These
resultsare in agreement with earlierstudiesin ourlaboratory
and others [11–15]. Lipid peroxidation, due to free radi-
calsattackingcellularmembranes, resultsintheformationofOxidative Medicine and Cellular Longevity 5
the lipid peroxidationbyproducts including4-hydroxynone-
nal, malondialdehyde,andmany othertoxicaldehydeswhich
are highly reactive with TBA and toxictoneuronal perikarya,
axons, and oligodendrocytes [36]. This study reports an
increase in NOx concentrations after ischemia. Nitric oxide
(NO) is a potent oxidizing molecule capable of eliciting lipid
peroxidation and cellular damage [37]. It has been suggested
that NO has the ability to exert multiple cytotoxic eﬀects
including an increase in arachidonic acid metabolism as well
as the formation of peroxynitrite, ONOO−.N i t r i co x i d em a y
also damage DNA through nucleotide base deamination and
may trigger programmed cell death [38]. There was also
a signiﬁcant reduction in the level of glutathione in the
ischemichippocampal neurons.Glutathione,an endogenous
antioxidant found in animal cells, reacts with radicals and
providesprotectionfromfree radicaldamage.Bothincreased
levelof TBARS and reduced glutathionelevel in the ischemic
hippocampus suggest an increased load of free radicals
during ischemia-reperfusion injury.
Typically, equilibrium exists between the generation of
ROS and the antioxidant defenses, maintaining homeostatic
control over the cell’s oxidative state. Hippocampal neurons
may be particularly susceptible to oxidative stress because of
the high rate of oxidative metabolic activity and low level
of antioxidant enzymes. Glutathione is considered to be the
most important intracellular nonprotein thiol compound in
mammalian cells and plays a crucial role as a free radical
scavenger, particularly eﬀective against the hydroxyl radical,
for which there is no known enzymatic defense system.
Therefore, the ability of glutathione to nonenzymatically
scavenge both singlet oxygen and hydroxyl radical provides
a ﬁrst line of antioxidant defense [39]. There has been strong
evidence that glutathione depletion causes nerve cell death
after forebrain ischemia [14, 15]. The loss of glutathione
may cause mitochondrial damage, and the impairment of
mitochondrial function may lead to a decrease in cytosolic
glutathione. In addition to its critical role as a free radical
scavenger, glutathione may act as a redox modulator of
ionotropic receptors and serve as a neuroprotectant against
glutamate excitotoxicity, which together suggest that alter-
ations in glutathione status may be deleterious to normal
neuronal function [40, 41].
Since free radicals and energy depletion are increasingly
implicated as key mediators of neuronal injury, neuropro-
tective antioxidants and ATP level boosters are considered a
promising approach to limit the extent of neuronal cell loss.
Forinstance, many antioxidants are reported to reduce ROS-
mediated reactions and rescue hippocampal neurons from
ischemia-reperfusion-induced neuronal loss in animal mod-
els of forebrain ischemia [14, 15, 35, 42, 43]. Additionally,
statins protectagainst cerebralischemia by limiting oxidative
stress-induced damage [28–30].
In the present study, the administration of probucol to
ischemic rats oﬀered considerable protective eﬀect mani-
fested by the normalization of ATP level and increasing the
number of intact neurons in hippocampus. This observed
increase in ATP production by probucol was parallel to the
increase in the number of intact neurons in hippocampus,
which may point to the possible consideration that ATP
could be a key mechanism by which probucol attenuates
forebrain ischemia-induced neuronal damage. This hypoth-
esis is consistent with previous studies which have reported
that probucol increases ATP/ADP ratio which is essential for
mitochondria function in myocardial ischemia reperfusion
[25,44].Apossibleexplanationforthiseﬀectisthatprobucol
could improve substrate oxidation and mitochondrial oxida-
tive phosphorylation secondary to its powerful antioxidant
activity which preserves the activity of many mitochondrial
enzymes.
Probucol produced a signiﬁcant reduction of ischemia-
induced oxidative stress which may be attributed to at least
partly to the restoration of the non-protein-SH contents and
reduction in TBARS production. Probucol also signiﬁcantly
prevented the elevation in NOx concentrations. Probucol
attenuated the loss of total glutathione caused by forebrain
ischemia, which provided evidence that probucol treatment
decreases oxidative stress by restoring reduced level of the
natural antioxidant, glutathione. This may be achieved via
itsmodulatory actiononthealteredglutathionemetabolism.
The antioxidant activities of probucol have been previously
reported [18–21]. More recently, Asiri have reported that
probucol not only increases the activity of endogenous
antioxidant enzymes but also it increases the mRNA expres-
sion of antioxidant genes and inhibits apoptosis in cardiac
tissues with the consequent improvement in mitochondrial
oxidative phosphorylation and energy production [44].
4.Methods
4.1. Animals. A total of 75 adult male Wistar albino rats,
weighing 230–250g, were obtained from the Animal Care
Center, College of Pharmacy, King Saud University, Riyadh,
Saudi Arabia and were housed in metabolic cagesundercon-
trolled environmental conditions(25◦Can da12hlight/dar k
cycle). Animals had free access to pulverized standard rat
pellet food and tap water unless otherwise indicated. The
protocol of this study has been approved by the Research
Ethics Committee of the College of Pharmacy, King Saud
University, Riyadh, Saudi Arabia.
4.2. Drugs and Chemicals. Probucol (Sigma Chemical Co.,
S t .L o u i s ,M o ,U S A )w a sd i s s o l v e di nc o r no i la n da d m i n i s -
tered intraperitoneally (I.P) at a dose of 61mg/kg according
to previous studies [23, 25, 44]. Intraperitoneal injection
was selected because probucol is poorly absorbed from the
gastrointestinal tract, with only 2–8% of the dose reaching
the circulation[45]. Thiobarbituric acid was purchased from
Sigma Chemical Co. (St. Louis, Mo, USA), while Ellman’s
reagent (5-5 -dithiobis-2-nitrobenzoic acid; DTNB) was
purchased from Fluka Chemical Company (Switzerland).
All other chemicals were of the highest analytical grades
commercially available.
4.3. Experimental Treatment Protocols. 75 adult male Wistar
albino rats were randomly divided into 5 groups of 15
animals each. Rats in the ﬁrst group (control group) were
injected with the vehicle of probucol, corn oil, (0.5mL/200g6 Oxidative Medicine and Cellular Longevity
body weight/day, I.P.) for 7 successive days. Rats in the
second group (sham group) were subjected to sham-
operated ischemia and injected with the vehicle of probucol,
corn oil, for 7 successive days. Rats in the third group
(ischemia group) were injected with the same dose of corn
oil immediately after the induction of 10min forebrain
ischemia and continued for 7 successive days. Rats in the
fourth group (probucol group) were injected with probucol
(61mg/kg/day, I.P.) for 7 successive days. Rats in the ﬁfth
group (ischemia plus probucol group) were injected with
the same dose of probucol immediately after the induction
of 10min forebrain ischemia and continued for 7 successive
days.
4.4. Transient Forebrain Ischemia Model. Transient forebrain
ischemia was induced in the rats under general anaesthesia
(sodium pentobarbital; 30mg/kg, I.P.) with 2-vessel occlu-
sion combined with systemic hypotension according to the
method of Smith et al. [46] and Henrich-Noack et al. [47].
First, blood was gradually withdrawn from jugular vein into
a heparinized syringe to reduce systemic blood pressure
to 45–50mmHg. With the animal in supine, the common
carotid arteries were exposed by means of a ventral midline
neck incision. Both common carotid arteries were exposed,
separated from the vagus nerve, and occludedfor 10minutes
with microaneurysmal clips (Dieﬀenbach Bulldog Clamp,
25mm, straight, Germany). At the end of the occlusion
period, the clamps were released allowing the restoration
of carotid blood ﬂow, and the incision was sutured with 2-
0 silk sutures. In sham-operated animals, the arteries were
freed from connective tissue but were not occluded. Body
temperature was kept at 37◦C by using a controlled heating
pad and heating lamps throughout the entire period of
ischemia and post-ischemic recovery under anesthesia. A
rectal thermometer was used to monitor body temperature
(Apelex Rectal Thermometer, Panlab, Bagneux, France).
4.5. Histological Analysis of Hippocampal CA1 Region. Seven
days after ischemia, 5 rats from each groupwere anesthetized
with sodium pentobarbital (100mg/kg). Rats were then
transcardially perfused with cold saline followed by 4%
formalin in phosphate-buﬀered saline (0.1M; pH 7.4). The
brains were removed from the skull and ﬁxed in the same
ﬁxative for 24h. Thereafter, the brains were embedded in
paraﬃn, and 5μm thick sections were coronally cut at the
level of the dorsal hippocampus by a rotatory microtome
(Leica CM3050S, Leica Microsystems, Bensheim, Germany).
The segments of the hippocampal CA1 region per 1000-μm
lengths from bregma −3.3, −3.8, and −4.3 were counted for
viable cells. Tissue sections were stained with hematoxylin
and eosin. The hippocampal damage was determined by
counting the number of intact neurons in the stratum
pyramidal within the CA1 subﬁeld at a magniﬁcation of
20 (Nikkon E 600, digital camera DXM1200F, Nikon Cor-
poration, Tokyo, Japan). Only neurons with normal visible
nuclei were counted. The mean number of CA1 neurons
per millimeter linear length for both hemispheres in sections
of dorsal hippocampus was calculated for each group of
animals. An observer who was unaware of the condition for
each rat made all assessments of the histological sections.
4.6. Tissue Sampling. Seven days after ischemia, the remain-
ing 10 rats from each group were decapitated, brains were
quickly removed, and the hippocampi were harvested on a
cold stage. Hippocampi were washed with saline, blotted dry
on a ﬁlter paper, weighed and then 10% (w/v) homogenates
were made in 6% perchloric acid (for assessment of ATP)
and in ice-cold saline (for assessment of hippocampal tissue
contents of GSH, TBARS, and NOx, using Branson Soniﬁer
(VWR Scientiﬁc, Danburg, USA)
4.7. Assay of Lipid Peroxidation and Reduced Glutathione.
The degree of lipid peroxidation in the hippocampal neu-
ronal tissue was determined by measuring TBARS in the
supernatant tissue from homogenate [48]. The homogenates
were centrifuged at 3500rpm, and supernatant was collected
and used for the estimation of TBARS. The absorbance
was measured spectrophotometrically at 532nm, and the
concentrations were expressed as nmol TBARS/g wet tissue.
The tissue levels of the acid soluble thiols, GSH, were assayed
calorimetrically at 412nm according to the method of
Ellman [49], using a Shimadzu (Tokyo, Japan) spectropho-
tometer. The contents of GSH were expressed as μmol/g wet
tissue [14, 15].
4.8. Determination of Total Nitrate/Nitrite (NOx)C o n c e n -
trations in Hippocampal Tissue. Total nitrate/nitrite (NOx)
concentrations were measured as stable end product, nitrite,
according to the method of Miranda et al. [50]. The assay
is based on the reduction of nitrate by vanadium trichloride
combined with detection by the acidic griess reaction. The
diazotization of sulfanilic acid with nitrite at acidic pH and
subsequent coupling with N-(10 naphthyl)-ethylenediamine
produced an intensely colored product that is measured
spectrophotometrically at 540nm. The concentrations of
NOx were expressed as nmol/g wet tissue [14, 15].
4.9. Determination of Adenosine Triphosphate Production in
Hippocampal Tissue. Adenosine triphosphate was deter-
mined in hippocampal tissue using HPLC according to the
method of Botker et al. [51]. In brief, hippocampal tissue
was homogenized in ice-cold6% perchloricacid, centrifuged
at 1000rpm for 15min at 0.5◦C, and the supernatant ﬂuid
was injected into HPLC after neutralization to pH 6-7.
Chromatographic separation was performed at a ﬂow rate
of 1.2mL/min, using ODS-Hypersil, 150 × 4.6mm I.D.,
5μm column (Supelco SA, Gland, Switzerland) and 75mM
ammonium dihydrogen phosphate as mobile phase. The
peak elution was followed at 254nm. The concentrations of
ATP were expressed as nmol ATP/g wet tissue [14, 15].
4.10. Statistical Analysis. Diﬀerences between obtained val-
ues (mean ± S.E.M.) were carried out by one way analysis of
variance (ANOVA) followed by the Tukey-Kramer multiple
comparison test. A P value of 0.05 or less was taken as a
criterion for a statistically signiﬁcant diﬀerence.Oxidative Medicine and Cellular Longevity 7
5.Conclusions
Data from this study suggest that the administration of pro-
bucol protected rats from ischemia-induced brain injury.
This protection may be due to the reduction of oxidative
stress and boosting of hippocampal ATP levels. These obser-
vations suggest that probucol may be a clinically viable
protectiveagentagainst a variety ofconditionswhere cellular
damage is a consequence of oxidative stress and energy
depletion. In addition, probucol may have the potential to
be used in the preventionof neurodegenerative diseases such
as forebrain ischemia. However, otherclinical considerations
must also be taken into account, such as the diminishing
eﬀect of probucol on both LDL and HDL content. Neverthe-
less,theresultsofthisstudyopennewperspectivesfortheuse
of probucol in the treatment of neurodegenerative diseases
particularly those that are associated with or secondary to
myocardial ischemia.
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